The Netherlands declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger in 2024
Page 3 of 11 of this archive, newest first.
The dose that got you here and the dose that keeps you here
The commonest real-world strategy in this drug class is the least studied one.
The United Arab Emirates caps tirzepatide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What a laboratory knows about the material it receives
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Randomised withdrawal is the cleanest design in this field and the least discussed
The regain trajectories, arm by arm, with the estimands named.
Switzerland caps dulaglutide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What a split-sample exercise can establish, and what it cannot
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Australia declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Spain declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Turkey caps semaglutide prescribing to 19 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
A tested vial is evidence about a vial
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Saudi Arabia declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Sending the same vial twice, under two names
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
France declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Nigeria caps liraglutide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The named comparison we promised two years ago
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Why people actually stop, in the order they actually stop
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
The badge economy, and what it is actually certifying
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Australia caps exenatide prescribing to 4 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.